Comparative Pharmacology
Head-to-head clinical analysis: CHLORPROMAZINE HYDROCHLORIDE versus HALDOL SOLUTAB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORPROMAZINE HYDROCHLORIDE versus HALDOL SOLUTAB.
CHLORPROMAZINE HYDROCHLORIDE vs HALDOL SOLUTAB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antagonizes dopamine D2 receptors in the mesolimbic pathway; also blocks alpha-adrenergic, histamine H1, muscarinic, and serotonin receptors.
Haloperidol is a typical antipsychotic that primarily antagonizes dopamine D2 receptors in the mesolimbic pathway, also blocking alpha-adrenergic, histamine H1, and muscarinic receptors.
25-100 mg orally or intramuscularly every 4-6 hours; maximum 2 g/day orally or 1 g/day intramuscularly.
1 to 15 mg orally once daily (tablet or orally disintegrating tablet). For acute agitation, 2.5 to 10 mg intramuscularly every 1 to 8 hours. Maximum oral dose: 100 mg/day; maximum IM dose: 20 mg/day.
None Documented
None Documented
Terminal elimination half-life 30 ± 14 hours (range 20–70 hours); clinical context: requires multiple daily dosing in acute agitation, but long-acting IM formulations (not chlorpromazine) available; half-life increases with age and hepatic impairment.
Terminal elimination half-life averages 21 hours (range 12-38 hours) in healthy adults; clinically significant for once-daily dosing.
Primarily hepatic metabolism; renal excretion accounts for ~20% as unchanged drug and metabolites, with ~6% unchanged; biliary/fecal excretion ~80%, mainly as metabolites.
Renal (approximately 30-40% as metabolites, <1% unchanged); biliary/fecal (approximately 15-20%); significant enterohepatic recirculation.
Category C
Category C
Antipsychotic
Antipsychotic